99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 10, 2006, Pages 3997-4000

  Rodrigues, Margarida ^a,b   Li, Shuren ^c   Gabriel, Michael ^a   Heute, Dirk ^a   Greifeneder, Michaela ^b   Virgolini, Irene ^a  

^a University Clinic for Nuclear Medicine   (Austria)

^b Hietzing Hospital   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DEPREOTIDE TC 99M; FLUORODEOXYGLUCOSE F 18; RADIOACTIVE IODINE; SOMATOSTATIN RECEPTOR; DIAGNOSTIC AGENT; DRUG DERIVATIVE; SOMATOSTATIN; TECHNETIUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOLOGY; DEMOGRAPHY; ECHOGRAPHY; FEMALE; FOLLICULAR CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MORPHOLOGY; PAPILLARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCINTIGRAPHY; THYROID CANCER; COMPARATIVE STUDY; MIDDLE AGED; SCINTISCANNING; THYROID TUMOR;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; SOMATOSTATIN; THYROID NEOPLASMS;

EID: 33749580942     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-0825     Document Type: Article

References (20)

1. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Holzer S 2000 Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 89:202-217
2. Giammarile F, Hafdi Z, Bournaud C, Janier M, Houzard C, Desuzinges C, Itti R, Sassolas G, Borson-Chazot F 2003 Is [18F]-2-fluoro-2-deoxy-D-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake? Eur J Endocrinol 149:293-300
3. +/I-symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84:3228-3234
4. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306
5. Girelli ME, Busnardo B, Amerio R, Scotton G, Casara D, Betterle C, Piccolo M, Pelizzo MR 1985 Serum thyroglobulin levels in patients with well-differentiated thyroid cancer during suppression therapy: study on 429 patients. Eur J Nucl Med 10:252-254
6. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, Schober O, Lerch H, Brandt-Mainz K, Burchert W, Hiltermann G, Cremerius U, Biersack HJ 1999 Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26:1547-1552
7. Lind P, Kresnik E, Kumnig G, Gallowitsch HJ, Igerc I, Matschnig S, Gomez I 2003 18F-FDG-PET in the follow-up of thyroid cancer. Acta Med Austriaca 30:17-21
8. Ain KB, Taylor KD, Tofiq S, Venkataraman G 1997 Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 82:1857-1862
9. 111In-DTPA-D- Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 41:636-642
10. 18F-FDG PET. Eur J Nucl Med Mol Imaging 32:1144-1151
11. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, Jamar F, Pauwels S, Valkema R 1999 Radiolabeled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 10:23-29
12. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731
13. 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 32:148-155
14. Vallabhajosula S, Moyer BR, Lister-James J, McBride BJ, Lipszyc H, Lee H, Bastidas D, Dean RT 1996 Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med 37:1016-1022
15. Blum J, Handmaker H, Rinne N 1998 The utility of a somatostatin type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest 115:224-232
16. 99m-P829. Cancer Res 58:1850-1859
17. 99mTc- depreotide. Semin Nucl Med 32:92-96
18. Feine U, Leitzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schuenburg W 1996 Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37:1468-1472
19. 111In-pentreotide scintigraphy. J Nucl Med 43:889-895
20. Sarlis NJ 2001 Metastatic thyroid cancer unresponsive to conventional therapies: novel management approaches through translational clinical research. Curr Drug Targets Immune Endocr Metabol Disord 1:103-115